Executive Summary

North America accounted for 39.12% of the Endoscopic Retrograde Cholangiopancreatography (ERCP) Market in 2025, the largest single-region share on record, backed by established reimbursement pathways and early single-use scope rollout. The market itself stood at USD 1,730 Million that year and is projected to reach USD 3,160 Million by 2035, a CAGR of 6.20% across 2025-2035.

Iterative accessory and duodenoscope clearance under the US FDA’s 510(k) pathway is shortening replacement cycles, while ISO 8600-1:2025 has reset verification and documentation requirements for endoscopes entering clinical use. Rising pancreatic cancer incidence across China and India is pulling procedure volume higher.

Asia-Pacific is the fastest-growing region, expanding at a 9.92% CAGR through 2035. Endotherapy Devices lead the product segmentation; Biliary Stenting leads by procedure type.

Reprocessing and channel-inspection costs under ANSI/AAMI ST91:2021 add a structural cost floor to reusable duodenoscope fleets. Competition turns on regulatory clearance speed, procedural evidence and installed endoscopy-suite base rather than on price alone.

Key Takeaways

• From USD 1,730.00 Million in 2025, the market reaches USD 3,160.00 Million by 2035 at 6.2% a year.
• Endotherapy Devices is the largest product category.
• Biliary Stenting is the largest procedure category.
• North America accounted for 39.1% of the market in 2025.
• Asia-Pacific is the fastest-growing region through 2035.
• 10 suppliers are profiled.

Market Definition and Scope

Duodenoscopes, cholangioscopes, sphincterotomes, guidewires, stents, retrieval balloons and baskets define the device boundary of the Endoscopic Retrograde Cholangiopancreatography (ERCP) Market, together with the video processors, light sources and electrosurgical generators that support them. These instruments are used to cannulate the bile and pancreatic ducts and treat obstruction through biliary sphincterotomy, stenting, dilatation, stone extraction and tissue sampling, performed across hospitals, ambulatory surgical centres and specialty gastroenterology clinics.

The boundary excludes colon capsule endoscopy, diagnostic upper gastrointestinal endoscopy without duct cannulation, and percutaneous transhepatic cholangiography, each governed by distinct coverage and device-clearance pathways.

Growth Drivers and Restraints

FDA 510(k) Clearance Is Shortening Duodenoscope and Accessory Replacement Cycles

The 510(k) premarket notification pathway lets manufacturers bring incremental duodenoscope, sphincterotome and stent design changes to US clinical use as Class II devices rather than through the longer PMA route. That clearance speed transmits directly into the Endoscopes and Endotherapy Devices segments, where hospitals replace elevator-mechanism duodenoscopes and single-use accessories on shorter cycles than the installed base once supported. ISO 8600-1:2025 has in parallel reset the verification and documentation baseline manufacturers must meet before filing, and the resulting design-history records themselves fall under FDA’s 21 CFR Part 11 controls on electronic records and signatures, tightening the audit trail behind each submission.

Rising Pancreaticobiliary Disease Incidence in China and India Is Pulling Asia-Pacific Procedure Volume

Training-centre investment across the region is expanding the pool of endoscopists able to perform ERCP, and rising pancreatic cancer incidence in China and India is widening the patient pool requiring biliary drainage and stone extraction. That combination is the mechanism behind Asia-Pacific’s 9.92% CAGR through 2035, the fastest of any region tracked. India’s Central Drugs Standard Control Organisation (CDSCO) requires import registration under the Medical Device Rules before new-generation duodenoscopes and stone-extraction accessories reach these training centres, adding a step ahead of each installation. The effect concentrates in Biliary Stenting and Stone Extraction procedure volume, and in Endoscopes and Endotherapy Devices sales tied to new training-centre installations rather than replacement of an existing base.

EU MDR Compliance and Single-Use Scope Rollout Are Resetting the North American and European Base

EU MDR recertification is pushing European hospitals toward device families with current technical documentation, and national health technology assessment (HTA) bodies factor that compliance status into reimbursement review before hospitals commit budget to new scope fleets. Germany and France are pairing that shift with early AI-imaging adoption inside ERCP suites, where endoscopic image data processed for diagnostic support falls under GDPR’s health-data provisions. North America shows the same substitution from the demand side: established reimbursement pathways and an early single-use duodenoscope rollout are the mechanism behind its 39.12% share of the market in 2025. Both regions route the effect into the Endoscopes segment, where single-use and MDR-compliant reusable designs are displacing older elevator-mechanism scopes.

Channel-Inspection Requirements Under ANSI/AAMI ST91:2021 Raise the Cost of Reusable Duodenoscope Fleets

ANSI/AAMI ST91:2021 recommends lighted-magnification inspection of endoscope channels and periodic borescope checks to catch occult damage before reprocessing failures reach a patient. AAMI itself flags borescope cost and the added reprocessing turnaround time as the principal obstacles to adoption. Hospital endoscopy suites and ambulatory surgical centres running reusable duodenoscope fleets absorb that cost most directly, and a share of that spend is now diverting toward single-use duodenoscopes instead of channel-inspection equipment.

Local Coverage Determination Consolidation Adds Reimbursement Uncertainty for Endoscopic GI Claims

Medicare Administrative Contractors periodically retire procedure-specific Local Coverage Determinations and fold them into a single jurisdiction-wide policy, as Noridian did in September 2025 when it retired LCD L38826 into a unified JE determination. Billing teams covering endoscopic gastrointestinal procedures across Noridian’s western jurisdictions must re-map coverage criteria against the consolidated document, cross-referencing the CMS reimbursement codes and CPT/HCPCS codes billed for each ERCP encounter. That burden falls hardest on community hospitals and ambulatory centres with thin revenue-cycle staff, the same providers most exposed to CDC-tracked growth in pancreaticobiliary disease burden that is pushing procedure volume higher even as coverage policy is rewritten.

Market Trends

Endotherapy Devices Are Displacing Adjunct Surgical Intervention in Biliary Obstruction

Cannulas, sphincterotomes, stents and retrieval baskets passed through the endoscope’s working channel are increasingly the first-line response to biliary obstruction and stone disease, ahead of open or laparoscopic alternatives. Most reach the market through the FDA’s 510(k) clearance route, and CMS reimbursement under existing CPT and HCPCS codes for ERCP gives these devices a coverage path that a new surgical technique would still have to establish. Gastroenterology-led endoscopy suites absorb most of the volume, and the effect is expected to keep pulling consumable spend away from single-procedure surgical intervention through 2035.

Single-Use Duodenoscopes Are Gaining Share as Reprocessing Standards Tighten

ISO 8600-1:2025 and ANSI/AAMI ST91:2021 have both raised the documentation and inspection bar for reusable endoscopes, tightening a reprocessing standard that CDC-investigated infection clusters had already put under scrutiny. North America’s early single-use scope rollout, built on devices cleared through FDA’s 510(k) and De Novo pathways, shows hospitals shifting a portion of the duodenoscope fleet to single-use models instead of absorbing added reprocessing cost. The change concentrates in the Endoscopes segment and in facilities running high ERCP volume, where the labor cost of channel inspection is hardest to staff around. Single-use adoption through 2035 is likely to track the pace at which hospital systems roll out ST91-compliant inspection programs.

AI-Assisted Imaging Is Moving From Pilot to Adopted Use in European ERCP Suites

Germany and France are pairing EU MDR and IVDR recertification with AI-imaging adoption inside ERCP suites, using image-assist software to support duct cannulation and stricture characterization during the procedure rather than as a standalone diagnostic pilot. Coverage still runs through national HTA assessment once a device clears MDR conformity, and algorithm validation studies increasingly register on ClinicalTrials.gov and follow ICH GCP to satisfy both the Notified Body and the payer. The pairing gives device makers a route to bundle software with MDR-compliant hardware at recertification, and it makes Visualization Systems the segment most exposed to the next wave of European procurement.

Segment Analysis

Product

• Endoscopes – Flexible duodenoscopes with a side-viewing optical tip and elevator mechanism used to navigate through the mouth into the duodenum for accessing the bile and pancreatic ducts

• Duodenoscopes
• Cholangioscopes
• Ultrasound Endoscopes
• Endotherapy Devices (largest) – Catheters, sphincterotomes, guidewires, stents, baskets, and balloons passed through the endoscope’s working channel to cannulate ducts and treat obstructions or stones

• Cannulas
• Sphincterotomes
• Guidewires
• Stents

• Plastic Stents
• Metal Stents
• Retrieval Devices

• Retrieval Balloons
• Retrieval Baskets
• Visualization Systems – Video processors, light sources, and monitors that capture and display the endoscopic image feed to guide the physician during the procedure

• Video Processors
• Light Sources
• Monitors
• Energy Devices – Electrosurgical generators and related probes that deliver cutting or coagulation current for sphincterotomy and tissue ablation during the procedure

• Electrosurgical Generators
• Argon Plasma Coagulators
• Others – Accessories and consumables such as biopsy forceps, contrast injection needles, mouthguards, and cleaning or disinfection equipment that support the procedure

Endotherapy devices lead the product axis in 2025, the position resting on per-procedure consumption of cannulas, sphincterotomes, guidewires, stents and retrieval baskets against a comparatively fixed base of duodenoscopes. Endoscopes carry high capital cost and a multi-year service life, so replacement cycles lag procedure growth, while endotherapy items are purchased against each case rather than each capital budget cycle. That consumable-pull-through pattern ties endotherapy revenue to procedure volume directly. Visualization systems are gaining pace fastest, as hospitals pair video processors and light sources with enhanced image review during cannulation and stricture assessment. The shift follows endoscopists substituting better visualization for repeat cannulation attempts, cutting procedure time and complication risk without a new endoscope purchase.

Procedure

• Biliary Sphincterotomy – An endoscopic procedure that cuts the sphincter of Oddi muscle to widen the bile duct opening and enable instrument access or drainage

• Pull-Type Sphincterotomy
• Needle-Knife Sphincterotomy
• Transpancreatic Sphincterotomy
• Balloon Sphincteroplasty
• Biliary Stenting (largest) – Placement of a plastic or metal tube within the bile duct to hold it open and restore bile flow past an obstruction

• Plastic Stents
• Self-Expandable Metal Stents

• Covered
• Uncovered
• Partially Covered
• Biliary Dilatation – Use of a balloon or catheter to widen a narrowed segment of the bile duct without cutting tissue

• Balloon Dilatation
• Bougie Dilatation
• Stone Extraction – Removal of gallstones or bile duct stones using baskets, balloons, or other retrieval devices passed through the endoscope

• Balloon Extraction
• Basket Extraction
• Mechanical Lithotripsy

• Through-the-Scope Baskets
• Emergency Lithotripsy
• Electrohydraulic/Laser Lithotripsy
• Tissue Sampling – Collection of cells or tissue from the bile duct or pancreas via brushing or biopsy for laboratory diagnosis

• Brush Cytology
• Forceps Biopsy
• Fine-Needle Aspiration

Biliary stenting leads procedure volume in 2025, the default drainage intervention for malignant and benign biliary obstruction across oncology and hepatobiliary referral pathways. Plastic stents cover routine short-term drainage while self-expandable metal stents capture longer-patency oncology cases, giving the category reach across both cost-sensitive and complex indications. Stone extraction is advancing fastest, as mechanical and electrohydraulic or laser lithotripsy widen the share of duct stones clearable endoscopically rather than surgically. That substitution follows endoscopists adopting lithotripsy baskets for stones once considered too large for standard basket or balloon retrieval, reducing referral to open or laparoscopic duct exploration.

Regional Analysis

North America held 39.12% of the ERCP market in 2025, the largest of the five regions tracked. Its installed base of reprocessed duodenoscopes now anchors demand: the FDA’s Class I recall of Olympus’s MAJ-891 forceps/irrigation plug, covering 30,140 units and initiated in December 2024 over inadvertent biomaterial retention, is routing inspection, correction and repair volume through US hospital endoscopy units.

Europe ranks second by size, without a disclosed share, on a hospital base that procures endoscope maintenance through small, multi-year contracts rather than national tenders. Hull University Teaching Hospitals NHS Trust awarded a three-year flexible-endoscope maintenance contract to STERIS Solutions worth £70,216.13 in May 2025, and Bradford Teaching Hospitals covered twelve endoscopes under a separate 2025 award, a procurement pattern that fragments service revenue across individual trusts.

Asia-Pacific is the fastest-growing region, expanding at a 9.92% CAGR through the forecast period. India leads the region’s national growth, at a 7.1% CAGR, ahead of China’s 6.3%, as training-centre investment expands endoscopist capacity against rising pancreatic and biliary disease incidence in both countries.

Middle East & Africa carries no disclosed share or growth rate. Its ERCP volume concentrates in Gulf tertiary-referral hospitals serving GCC states and in South Africa’s private hospital networks, the two settings that currently hold the region’s specialist biliary-endoscopy capacity.

South America likewise carries no stated share or CAGR. Procurement in Brazil and Argentina runs largely through public hospital tenders rather than direct purchasing, concentrating endotherapy device demand within a smaller set of tertiary public health-system contracts rather than a broad private-hospital base.

Country Growth Comparison

India grows fastest at 7.1% and United States slowest at 2.0%, a spread of 5.1 percentage points.

Competitive Landscape

The ERCP market is led by a group of established endoscopy and endotherapy manufacturers rather than a single dominant supplier: Olympus Corporation, Boston Scientific Corporation, Medtronic plc, CONMED Corporation, FUJIFILM Holdings Corporation, Ambu A/S, Cook Group, HOYA Corporation, Karl Storz SE & Co. KG and Telemed Systems, Inc. Competition centers on installed duodenoscope base and the consumable pull-through it locks in, since cannulas, sphincterotomes, guidewires, stents and retrieval devices are repurchased against every procedure performed on that base. Regulatory clearance breadth, reprocessing and infection-control performance, manufacturing scale sufficient to hold quality-system audits across export markets, and GPO or IDN contract coverage further separate suppliers competing for hospital endoscopy-unit contracts.

Reprocessing failure is itself shaping near-term competitive standing: the FDA posted a Class I recall of Olympus Corporation of the Americas’ MAJ-891 forceps/irrigation plug in January 2025, covering 30,140 units in commerce and citing a labelling-design root cause for inadvertent biomaterial retention, a correction that puts inspection and replacement demand directly onto Olympus’s existing hospital accounts. AAMI ST91:2021 already recommends periodic borescope inspection of endoscope channels, a routine that will keep surfacing comparable defects across the installed base and route repair volume toward whichever supplier holds the service contract.

Strategic Outlook

The clearest whitespace sits in stone extraction and visualization consumables tied to Asia-Pacific’s training-centre buildout: suppliers that localize lithotripsy and imaging accessories against India’s and China’s expanding endoscopist base capture procedure growth ahead of capital-equipment replacement cycles, provided device registration keeps pace with each country’s training-centre rollout.

By 2035, competitive weight is expected to shift further toward consumable pull-through and reprocessing compliance, as recall-driven inspection regimes and fragmented European maintenance procurement keep service and accessory revenue, not new endoscope placements, the primary growth line for established suppliers with the broadest existing hospital installed base.

Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Report Scope